Neuroscience

The Neuroscience Group aims to discover and develop treatments for neurodegenerative and psychiatric diseases.

The group addresses neurodegeneration by seeking to discover disease-modifying treatments which ameliorate the toxic effects of protein misfolding, the shared mechanism underlying disorders such as Huntington's, Parkinson's and Alzheimer's disease.

The group’s strategy for psychopharmacologicals is to develop “best in class” compounds for novel, clinically validated targets.

The Neuroscience Group concentrates on neurodegenerative and neurological disorders such as Huntington's, Parkinson's and Alzheimer's disease, as well as on psychiatric diseases.

 

 

Selected publications

• Abramowski D.; Wiederhold K.H.; Furrer U.; Jaton A.L.; Neuenschwander A.; Runser M.J.; Danner S.; Reichwald J.; Ammaturo D.; Staab D.; Stoeckli M.; Rueeger H.; Neumann U.; Staufenbiel M. Dynamics of Abeta Turnover and Deposition in Different APP Transgenic Mouse Models Following Gamma-Secretase Inhibition. J Pharmacol Exp Ther. (2008); Vol 327 (2); 411 - 24.
• Gasparini F.; Bilbe G.; Gomez-Mancilla B.; Spooren W. mGluR5 antagonists: discovery, characterization and drug development. Curr Opin Drug Discov Devel.  (2008); Vol 11(5); 655 - 65.
• Bibel M.; Richer J.; Lacroix E.; Barde Y-A.Generation of a defined and uniform population of CNS progenitors and neurons from mouse embryonic stem cells. Nature Protocols Vol. (2007); 2 (5); 1034 - 43.